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Background: Adverse drug reactions (ADRs) are an important cause of harm in children. Current data are
incomplete due to methodological differences between studies: only half of all studies provide drug data, incidence
rates vary (0.6% to 16.8%) and very few studies provide data on causality, severity and risk factors of pediatric ADRs.
We aimed to determine the incidence of ADRs in hospitalized children, to characterize these ADRs in terms of type,
drug etiology, causality and severity and to identify risk factors.
Methods: We undertook a year-long, prospective observational cohort study of admissions to a single UK pediatric
medical and surgical secondary and tertiary referral center (Alder Hey, Liverpool, UK). Children between 0 and 16
years 11 months old and admitted for more than 48 hours were included. Observed outcomes were occurrence of
ADR and time to first ADR for the risk factor analysis.
Results: A total of 5,118 children (6,601 admissions) were included, 17.7% of whom experienced at least one ADR.
Opiate analgesics and drugs used in general anesthesia (GA) accounted for more than 50% of all drugs implicated
in ADRs. Of these ADRs, 0.9% caused permanent harm or required admission to a higher level of care. Children who
underwent GA were at more than six times the risk of developing an ADR than children without a GA (hazard ratio
(HR) 6.40; 95% confidence interval (CI) 5.30 to 7.70). Other factors increasing the risk of an ADR were increasing age
(HR 1.06 for each year; 95% CI 1.04 to 1.07), increasing number of drugs (HR 1.25 for each additional drug; 95% CI
1.22 to 1.28) and oncological treatment (HR 1.90; 95% CI 1.40 to 2.60).
Conclusions: ADRs are common in hospitalized children and children who had undergone a GA had more than six
times the risk of developing an ADR. GA agents and opiate analgesics are a significant cause of ADRs and have
been underrepresented in previous studies. This is a concern in view of the increasing number of pediatric
short-stay surgeries.
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Adverse drug reactions (ADRs) are an important cause
of iatrogenic morbidity and mortality in patients of all
ages [1-5]. ADRs in children may differ from those in
adults due to age-dependent physiological characteristics
which affect the pharmacokinetics and pharmacodynam-
ics of drugs [1,3,6,7].
A recent systematic review of 102 studies of ADRs in
children by Smyth et al. [8] showed that previous studies
have differed widely in their definition of ADRs, clinical
settings, and age range of children studied and a high
proportion had major shortcomings in design and/or
reporting. A large proportion did not report data on in-
cidence, severity and causality of ADRs or drugs and
reaction types implicated. Study sizes for the 21 pro-
spective pediatric inpatient studies ranged from 81 to
3,726 patients; three of these 21 studies were large
(n >1,000). Reported incidence rates for hospitalized
children experiencing an ADR ranged from 0.6% to 16.8%.
A recent prospective analysis of 3,695 patient-episodes in
adults [5] reported an ADR incidence rate of 14.7% with
estimated rates in earlier studies ranging from 0.86% [9]
to 37% [10] depending on study population, design and
setting.
Data on the drugs associated with ADRs were only
available in 52 of 102 studies investigated in the system-
atic review by Smyth et al. and many did not report the
associated clinical presentations. Although 70% of the
studies analyzed in this systematic review referred to a
causality assessment, less than one third reported this in
detail. Of 34 studies which assessed the severity of
ADRs, only 20 provided a reference for the assessment
tool used, with proportions of severe reactions reported
from 0 to 66.7%. Only 14 studies provided data on the
avoidability of ADRs and outcomes differed widely, with
7% to 98% of ADRs deemed definitely/possibly avoid-
able. Furthermore, few studies to date have investigated
risk factors for ADRs in children. In the systematic re-
view, female gender (10/19 studies), increasing number
of drugs (16/17 studies), off-label use (3/3 studies) and
oncological treatment (2 studies) were identifiable risk
factors [8]. More recently, Rashed et al. conducted a
prospective multicenter study of 1,278 hospitalized chil-
dren (1,340 admissions) and, using multivariate logistic
regression, found that multiple drug use and older age
were risk factors for ADRs [2].
Reducing the impact of pediatric ADRs requires pre-
cise estimates of the incidence and nature of ADRs.
Given the discordances in the extant literature, we
designed a study large enough and of sufficiently robust
design to overcome the problems identified in the previ-
ous literature. The aim of this study was to determine
the incidence of ADRs in pediatric medical and surgical
inpatients, to characterize those ADRs identified interms of type, medication implicated, causality, and
severity, and to identify factors which increase the risk
of ADRs.
Methods
Study design and setting
The study was conducted over one year in a single sec-
ondary and tertiary pediatric referral center, Alder Hey
Children’s National Health Service (NHS) Foundation
Trust, which treats 200,000 children a year from the
North West of England, North Wales, Shropshire and
the Isle of Man. The Accident and Emergency depart-
ment treats more than 60,000 children every year. There
are 274 inpatient beds, including a pediatric ICU (PICU).
Although neonates were included in the study, the hos-
pital does not have a designated neonatal intensive care
unit (NICU) (since a NICU exists in a nearby tertiary
maternity center). Any neonates requiring surgical man-
agement (including cardiac surgery) are transferred to
Alder Hey and cared for on the PICU (if ventilated), the
cardiac ward, or on the neonatal ward (surgical patients
requiring ventilation). The study population comprised
children between 0 and 16 years 11 months old on ad-
mission, who were inpatients between 1 October 2009
and 30 September 2010. Extensive pilot work before the
study established that the study team did not have the
resources to carry out a detailed review of every in-
patient every day. In 2008, a total of 39,747 inpatient ad-
missions were recorded (emergency admissions, elective
admissions and day-case attendances); of those 10,943
stayed longer than 24 hours and 5,357 stayed longer
than 48 hours. A pragmatic decision was thus made
to include only those children who had been inpatients
for >48 hours.
Admissions included in this study were elective and
emergency admissions of all pediatric medical and
pediatric surgical specialities. Observations were carried
out on 17 wards, including oncology wards and the high
dependency unit (HDU). Patients were not observed
while admitted to the PICU, theater, recovery or the de-
partment of radiology. We used the established hospital
database for the recruitment of patients to the study.
Electronic files containing a list of all children in the
study population who met the inclusion criteria were
automatically generated every 12 hours. Each child was
followed up every 48 or 72 hours on weekdays and
weekends, respectively, by one member of a multidiscip-
linary team of researchers comprising two research phar-
macists, one research nurse and a pediatrician. We
recorded details of all drugs administered on the wards,
occurrence of new symptoms or those that had wors-
ened and abnormal results that may have indicated the
occurrence of an ADR, taking into account the case his-
tory, the ADR profiles of medication and the temporal
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normal results included laboratory data and imaging re-
ports, which are recorded electronically on the hospital
database. These were routinely screened every time the
patient was reviewed and any abnormal results recorded.
We aimed to include all potential reactions to any medi-
cation administered in hospital (including those started
prior to admission) and presenting after admission to a
ward; each reaction was followed up with a detailed as-
sessment by one research team member. Suspected reac-
tions to certain blood products, total parental nutrition
and intravenous hydration fluids were excluded from
this study (Table 1).
ADR definition
We defined ADRs according to the definition of Edwards
and Aronson: an ADR is ‘an appreciably harmful or un-
pleasant reaction, resulting from an intervention related
to the use of a medicinal product, which predicts hazard
from future administration and warrants prevention or
specific treatment, or alteration of the dose regimen, or
withdrawal of the product’ [11]. Prescribing errors, admin-
istration errors and intentional drug overdoses were thus
not considered ADRs in this study.
Causality and severity assessment of ADRs
The ADR case report was assessed independently by a
research nurse, a research pharmacist and a pediatrician
using the Liverpool ADR causality assessment tool asTable 1 Excluded medicinal products
Excluded Included
Topical
anesthetics
Lidocaine 2.5%, prilocaine 2.5% cream
(EMLA®) or tetracaine 4% gel (Ametop®)
LAT gel (lid
Ranitidine Ranitidine added to TPN Ranitidine
Heparin Heparin administered as intermittent
intravenous heparin flush.
Intermitten
continuou
Total parenteral
nutrition (TPN)
Total parenteral nutrition (TPN)
Intravenous
hydration fluids
Intravenous hydration fluids Any drugs
Rectal washouts Rectal washouts with sodium chloride 0.9%
Blood products Red cells Antithrom
Platelets Dried prot
Cryoprecipitate Drotrecog
Albumin solutions Factor VIIa
Fresh frozen plasma Factor VIII
Factor VIII
Factor IX f
Factor XIII
Protein C c
Oxygen therapy Oxygen therapyunlikely, possible, probable or definite [12]. Outcome
reporting was based on consensus agreement among the
three assessors; if agreement could not be achieved the
case was referred to a panel of two of the senior investi-
gators (MAT, RLS, AJN and MPir); each panel reached
consensus about causality. Our estimate for the overall
incidence was based on the sum of probable and definite
ADRs only, as these ADRs are deemed to have a low
probability of the underlying disease being responsible
for the reaction. The severity of ADRs was assessed
using the Hartwig scale [13]. Reactions classified as level
four and above were considered severe.
Incidence
Incidence was calculated in two ways by dividing: (i) the
number of admissions in which at least one ADR oc-
curred by the total number of admissions regardless of
drug exposure; and (ii) the number of children with at
least one ADR by the total number of children regard-
less of drug exposure.
Risk factor analysis
Time from admission to first ADR was calculated in
days. For patients admitted to PICU this was time to
first ADR prior to PICU admission. If no ADR occurred
prior to PICU admission, time from admission to first
ADR was censored at the time of admission to PICU.
ADRs occurring after PICU were included in the overall
incidence calculation. For the analysis of risk factors,ocaine 4% and adrenaline 0.1% and tetracaine 0.5% gel)
administered otherwise
t intravenous injection other than heparin flush, heparin administered as
s intravenous infusion or as subcutaneous injection.
added to intravenous fluids
bin III concentrate
hrombin complex
in alfa (activated)
(recombinant)
fraction, dried
inhibitor by-passing fraction
raction, dried
fraction, dried
oncentrate
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sion only were included. We assessed age, gender, num-
ber of drugs, receipt of a general anesthesia (GA) and
oncology status as risk factors. Oncology patients were
defined as those requiring on-going medical treatment
for a malignancy of a solid organ or of the hematopoietic
system. The number of drugs refers to the daily number
of drugs administered to the patient on the ward. This
risk factor was treated as a continuous, time-varying co-
variate in the multivariate model. The factor ‘received a
GA’ was considered to be present from the first day the
patient received a GA until discharge from the hospital.
This risk factor was treated as a binary, time-varying
variable in the multivariate model that takes the value
zero on days up to the GA and one thereafter for the
remaining days of a patient’s admission.
Statistical methods
Time to first ADR was compared between groups using
a log-rank test (extending to a log rank test for trend
when appropriate) and Kaplan-Meier curves estimated.
A Cox proportional hazards regression model for an
ADR was fit to the data. Results are given in terms of
the hazard ratio (HR) and associated 95% confidence
interval (95% CI). Due to their clinical importance, all of
the risk factor variables are included in a multivariate
model. The assumptions of the model were assessed as
follows. The proportional hazards assumption for each
covariate was investigated using log cumulative hazard
plots and Schoenfeld residual plots. The assumption was
also tested by including a time-dependent covariate ef-
fect. Deviance residuals were plotted against the linear
predictor to look for mis-modelling of the data and em-
pirical validation of the model was done using a data
splitting technique to assess model accuracy. Patients
with missing prescription details for the entire duration
of the admission were excluded from the analysis. The
inclusion of patients with partially missing prescription
details (for example, prescription details for day of dis-
charge) was assessed on a case-by-case basis. They were
only included if it was considered unlikely that this
would have led to missing an ADR. Furthermore, any
potentially missed ADRs towards the end of the stay are
unlikely to have had an impact on the risk factor analysis
as we used time to first ADR as the observed outcome.
Investigations were based on clinical indication. For
example, hypertension could only be identified if a
child’s blood pressure was monitored for clinical reasons.
We recorded ADRs observed between 1 October 2009
and 30 September 2010. Patients admitted between 28
and 30 September 2009 or discharged after 30 September
2010 who experienced an ADR before 1 October 2009
or after 30 September 2010, respectively, were counted
as admissions without ADR in the analysis. Consequently,there are 180 admissions that lie outside the observa-
tion period where an ADR may have occurred that has
not been recorded. All statistical analysis was carried
out using the statistical software package R (version
2.13.2) using a two-sided significance level of 0.05 (5%)
throughout.
Reporting
This study was reported according to the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [14].
Ethics
This study used routinely collected clinical data in
an anonymized format. The Chair of the Liverpool
Paediatric LREC informed us that this study did not
require individual patient consent or review by an
Ethics Committee.
Results and discussion
Participants and descriptive data
A total of 6,825 eligible admissions were identified. Of
these, 181 (2.7%) admissions could not be included due
to missing data. Forty-three patients spent their entire
admission on PICU and were thus excluded. Conse-
quently, 6,601 admissions of 5,118 children were in-
cluded in the study; of these, 827 were also admitted to
PICU with 45.2% being cardiology or cardiothoracic pa-
tients. The median length of follow up time across ad-
missions was five days (interquartile range (IQR) 3 to 8
days, range 2 to 280 days). The median age on admission
was 3.4 years (IQR 0.6 to 10.7); 2,297 (44.8%) were fe-
male. A total of 4,284 (83.7%) children had one admis-
sion and 834 children had more than one admission. A
total of 2,856 children (55.8%) underwent at least one
GA during 3,265 admissions (49.4%); 114 children
(2.2%) were oncology patients. In total, 2,934 suspected
ADRs were assessed. After causality assessment, 213
(7.3%) of the suspected ADRs were deemed definite,
1,233 (42.0%) probable, 896 (30.5%) possible and 592
(20.2%) unlikely. Consensus was reached independently
in 1,805 cases (61.5%) and by panel decision in 1,128
cases (38.5%). All definite and probable ADRs were
included in the further analysis (total number 1,446;
Figure 1). The overall incidence of definite and probable
ADRs based on admissions was 15.9% (95% CI 15.0 to
16.8) and 17.7% when based on numbers of patients
(95% CI 16.7 to 18.8). The ADR incidence for patients
with only one admission was 14.7% (95% CI 13.7 to
15.9). For patients with more than one admission, the
incidence per admission was 18.0% (95% CI 16.4 to 19.6)
but 32.7% per patient (95% CI 29.6 to 35.9). A total of
0.9% of the ADRs were severe and required patient
transfer to a higher level of care. One patient sustained
1446 ADRs
6,601 admissions/5,118 patients
PICU from day 1 => censored from day 1 
356 admissions; 43 ADRs 
PICU after day 1 => censored from time of PICU admission
117 ADRs
1,157 ADRs
6,094 admissions/4,724 patients
694 ADRs
694 patients with at least one ADR
4,030 patients without ADR
151 admissions without drug exposure
Univariate and multivariate 
analysis 
769 patients with >1 admission
318 ADRs ‘multi admissions’
129 ADRs with identical start date 
(>1 ADR/day during same admission = 1 ADR event)
118 patients had a total >1 ADRs during first admission  
145 ADRs = ‘multi event’ during first admission
Figure 1 Flowchart outlining the number of admissions included in the univariate and multivariate risk factor analysis.
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tine). No ADR resulted in death. Details of all severe re-
actions by reaction type and associated drugs are listed
(Tables 2 and 3). Common ADR types and ADRs ob-
served following GA are summarized in Table 4.
To our knowledge, this is the largest pediatric in-
hospital study investigating ADRs. The study population
represents a wide range of pediatric medical and surgical
specialities, given the nature of the hospital as a regional
center. Our methodology included causality and severity
assessments using validated tools. An avoidability as-
sessment was not undertaken because of the lack ofTable 2 Assessment of severity using the Hartwig severity sca
Severity
level
Description
1 Required no change in treatment
2 Drug dosing or frequency changed
3 Required treatment or drug administration discontinued
4 Resulted in patient transfer to higher level of care
5 Caused permanent harm to patient or significant hemodyn
6 Directly or indirectly resulted in patient death
aDenominator was the total number of probable or definite ADRs. ADRs, adverse drappropriate tools and imperfect definitions of prevent-
ability as highlighted recently by Ferner and Aronson
[15]. The most frequently used assessment tools were
Schumock and Thornton [16] and Hallas [17], which
are based on appropriateness of prescribing or treat-
ment choice. These tools might be used successfully to
improve prescribing practice in specific clinical circum-
stances. However, they become problematic when treat-
ment is guided by multiple sources of tertiary pediatric
specialist advice. Rashed et al. [2] reported an overall
ADR incidence of 16.5 (95% CI 14.5 to 18.7) per patient
in their multicenter study of 1,278 patients (1,340le
Number of ADRs at each severity levela
Number %
322 22.3%
66 4.6%
1,046 72.3%
12 0.8%
amic instability 1 0.1%
0 0%
ug reactions.
Table 3 Severe reactions (Hartwig scale ≥4) by reaction type and medication implicated
Severity level ADR type (count) Medication implicated (count) Admission to PICU/ HDU (if > once)
4 Cardiac failure (1) Bisoprolol (1), Carvedilol (1)a HDU
Sedation withdrawal (1)b Fentanyl (1), Midazolam (1), Promethazine (1) ,
Chloral hydrate (1)
PICU
Raised INR and hemorrhage (1) Warfarin (1) HDU
Pulmonary edema (1) Diazoxide (1) HDU
Respiratory depression (5) Fentanyl (4), Ketamine (2), Midazolam (1), PICU (3)c HDU (2)
Respiratory arrest (2) Fentanyl (2), Sevoflurane (1), Isoflurane (1), Ketamine (1) PICU, HDU
5 Peripheral neuropathy (1) Vincristine (1) N/A
aBoth drugs caused significant fluid retention in this patient; bthis patient had been on sedating drugs for 10 days by the time withdrawal became clinically
significant; cADR was not the only factor leading to PICU admission; other clinical factors may also have contributed. ADR adverse drug reaction, HDU high
dependency unit, INR international normalized ratio, PICU pediatric ICU.
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comparable study in adults, observed an incidence of
14.7% per episode (admission) and 15.8% per patient.
However, both Rashed et al. and Davies et al. used the
Naranjo algorithm [18] for causality assessment and in-
cluded possible, probable and definite ADRs in theirTable 4 Common ADR types observed
Reaction type All reactions
N % of all re
Nausea and/or vomiting 400 27.5%
Pruritus 243 16.7%
Constipation 155 10.6%
Diarrhea (9/88 with vomiting) 88 6.0%
Somnolence (without cardio-respiratory symptoms) 50 3.4%
Respiratory depression (41)/arrest (3) 44 3.0%
Candidiasis 41 2.8%
Urinary retention 40 2.7%
Rash 31 2.1%
Hypokalemia 25 1.7%
Hypotension 22 1.5%
Hepatotoxicity(6)/increased transaminases (12)c 18 1.2%
Stomatitis 16 1.1%
Myoclonus 15 1.0%
Pancytopenia 13 <1%
Hyperglycemia 12 <1%
Hypertension 11 <1%
Allergic reactions 10 <1%
Pain (4/10 pain in jaw, 2/10 back pain) 10 <1%
Other reactions ( occurred <10 times) 213 14.6%
Total 1,457
aIf the same patient experienced two types of reactions to the same medication(s)
listed here as two reaction types, for example, a patient with respiratory depression
occurred post theater AND drugs given in theater and/or used in post-operative pa
Additionally, if other parameters of liver function such as bilirubin and INR were als
general anesthesia; N number, INR international normalized ratio.calculations. In our study, we only included probable
and definite ADRs as these have a low probability of
the underlying disease causing the reaction. Had we in-
cluded possible ADRs, our overall ADR incidence rate
would have been more than 25% per child (data not
shown) which is much higher than in adults. OneReaction following GAb
actionsa N % of reaction types, where reaction followed GA
295 73.8%
232 95.5%
107 69.0%
0 0.0%
34 68.0%
43 97.7%
0 0.0%
37 92.5%
3 9.7%
0 0.0%
9 40.9%
1 5.6%
0 0.0%
14 93.3%
0 0.0%
0 0.0%
2 18.2%
3 30.0%
0 0.0%
65 30.5%
845 58.0%
at the same time this would have been reported as one ADR case but will be
and bradycardia = one ADR case, but is listed as two reactions; breaction
in management were implicated; ctransaminases were raised in all cases.
o raised, we classified this as hepatotoxicity. ADR, adverse drug reaction, GA
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have not been tested properly or at all in infants and
children.
Reaction types, drug classes implicated in ADRs and risk
factor analysis
The 10 most common reaction types together accounted
for 76.6% of all ADRs [see Additional file 1: Table S1].
Pruritus, respiratory depression and urinary retention
occurred almost exclusively in the post-anesthetic set-
ting. In more than two-thirds of patients with nausea/
vomiting, constipation or somnolence, drugs given dur-
ing the anesthetic and/or used in post-operative pain
management were implicated. Opioid analgesics and
anesthetic agents were the most commonly implicated
drug groups and accounted for 54% of all drugs associ-
ated with ADRs. Results of the univariate analysis are
shown in Table 5 and Figure 2. Multivariate risk factor
analysis of first admissions is shown in Table 6 and in-
dicated that the risk of an ADR was associated with a
GA, more than one medicine, being an oncology pa-
tient and age.
Most previous pediatric inpatient studies were carried
out in general pediatric settings [8] in which only a small
number of patients would have undergone GAs, thus
underrepresenting drugs used in pediatric peri- and
post-operative management. Rashed et al. [2] conducted
a pediatric study on general medical wards and reported
that anesthetics, which accounted for only 1% of all
prescriptions, were among the drugs most commonly
implicated in ADRs. In the two previous inpatient stud-
ies investigating pediatric surgical patients and providing
medication details, opiate analgesics were among the
two most commonly implicated drugs. However, GAs
were not included, perhaps because they were not spe-
cifically investigated [19,20]. The differences in our study
population, which included a large number of surgical
patients (but not those admitted to the PICU immedi-
ately post-operatively), are also reflected in the spectrumTable 5 Univariate analysis by categorical time invariant risk
Covariate Total
patient
Gender Male 2,602
Female 2,122
Age Infant (<1 years) 1,369
Pre-school (1 to 5 years) 1,259
School-aged (5 to 11 years) 1,105
Teenage (>11 years) 991
Oncology Yes 106
No 4,625
aOnly the first ADR was included in this analysis. ADR adverse drug reaction.and severity of common reaction types observed. Some
reaction types such as urinary retention and respiratory
depression/arrest occurred almost exclusively following
GA. Eight of the 12 reactions classified as severe in our
study occurred in post-operative patients and led to
transfer to the HDU or PICU (Table 3). Notably, the risk
of experiencing an ADR in patients undergoing a pro-
cedure under GA has not been assessed previously. In
addition, our study confirmed risk factors that have been
identified previously including increasing age, oncology
treatment, and number of drugs [2,21]. It is not entirely
clear why ADR risk increased with age, but is likely to
be due to many factors including lack of detection and
underreporting in younger or mentally disabled children
(where symptoms dependent on patient communication,
for example, nausea, pain, hallucinations, were under-
represented); acceptance of some common clinical mani-
festations such as vomiting and loose stools as being
‘normal’ in younger children; and reaction types such as
pruritus being mistaken for ‘unsettledness’ in infants.
The observational approach depends on documenta-
tion by the clinical team regarding signs and symptoms
and is, thus, a limitation of our study. A further limita-
tion of the study was the exclusion of PICU patients,
which is likely to have led to a lower overall ADR inci-
dence. We deliberately excluded PICU patients because
the causality assessment was more difficult and requires
different methodologies for detection. Any ADRs occur-
ring in patients admitted for less than 48 hours would
also not have been included in this study. However, if
such ADRs had required re-admission to hospital this
would have been captured in our admissions study [21]
and any ADRs requiring further management would
have probably led to an extension of stay beyond 48
hours. Thus, although we would have missed ADRs in
the time period of 0 to 48 hours, these were probably
the less serious ADRs. Despite intense surveillance, it is
possible that some ADRs were missed. The assessment
of symptoms due to the underlying condition andfactor
s
Number of patients
with ADRa
Log rank statistic
(P-value)
382 0.900
312
78 <0.001
155
231
230
649 <0.001
45
Figure 2 Cumulative incidence curves by categorical time invariant risk factor: (A) by age category, (B) gender and (C) oncology status.
Table 6 Risk factors for ADRs assessed by multivariate
analysis
Covariate HR (95% CI) P-val
Age on admission (in years) 1.06 (1.04 to 1.07) <0.00
Gender Female 1 0.30
Male 0.93 (0.80 to 1.08)
Number of drugs 1.25 (1.22 to 1.28) <0.00
Received a GA No 1 <0.00
Yes 6.38 (5.30 to 7.68)
Oncology No 1 <0.00
Yes 1.89 (1.36 to 2.63)
ADRs adverse drug reactions, CI confidence interval, GA general anesthesia,
HR hazard ratio.
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1
1
1
1
1differentiating these from those caused by drugs (for ex-
ample, tachycardia in patients being treated for acute
asthma) remains a challenge.Conclusions
Our data show that 17.7% of all children who spent
more than 48 hours as an in-patient experienced at least
one ADR. It is likely that our figures underestimated the
true incidence of adverse events that should be attrib-
uted to drugs as we excluded ‘possible’ and ‘unlikely’
ADRs. A total of 58% of the ADRs observed in our study
occurred in patients undergoing a procedure under GA
which, at the same time, increased the risk of developing
an ADR by more than six times. Our study did not as-
sess children who stayed in hospital for less than 48
hours. ADRs may also be an important problem in
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Given the current strategies to increase the proportion
of children having day case surgery [22,23], this warrants
further investigation.
Although less than 1% of reactions in our study were
classified as severe, this does not take into account what
impact an ADR might have on the child and/or the care-
giver. For instance, a teenage patient is likely to feel very
distressed about having to be catheterized because of
urinary retention or receive an enema to treat constipa-
tion. The most common reaction in our study was
vomiting, mainly observed in post-operative patients.
Vomiting is a common and non-specific symptom in
children and, thus, unlikely to be regarded as being par-
ticularly significant by clinicians. However, Diez reported
that parents placed a very high value on the distress
caused by postoperative vomiting [24]. In addition, par-
ents of children included in this study reported that
suspected ADRs cause them concern, irrespective of the
‘medical’ severity of the suspected reaction. On the other
hand, parents valued the proactive explanations of ADRs
given by oncologists and we suggest that a detailed dis-
cussion of this should form part of the preoperative as-
sessment [25].
In conclusion, ADRs in hospitalized children are com-
mon and the incidence is much greater than in adults.
Drugs used in perioperative management appear to be a
major risk factor for experiencing an ADR, thus system-
atic monitoring of common and severe adverse effects of
these drug groups would be an important step towards
improving their safety.
Additional file
: Table S1. Drug groups implicated in ADRs by
frequency with associated reaction types.
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